2m 2m 2m 2m 2m 2m 2m
ARMATA PHARMA (ARMP)
NYSE
$7.52-$0.41 (-5.11%)
Price as of Jun 03, 2026 4:10 PM EDT- $299.9MMarket Cap
- 310.36%1-Year Change
- BiotechnologyIndustry
ARMATA PHARMA (ARMP)
$7.52-$0.41 (-5.11%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -23.7M -31.11% | -34.4M +1.94% | -33.8M -3.56% | -35.0M +74.95% | |
Depreciation and Amortization Expense | 1.5M +15.55% | 1.3M +36.32% | 972,000 +8.97% | 892,000 -23.70% | |
Total Operating Expenses | 41.5M -12.75% | 47.6M +4.82% | 45.4M +6.98% | 42.5M +50.04% | |
Operating Profit | -36.6M -13.67% | -42.4M +3.78% | -40.9M +10.68% | -36.9M +55.09% | |
Interest Income | 388,000 -44.33% | 697,000 +289.39% | 179,000 +517.24% | 29,000 +480.00% | |
Interest Expense | N/A N/A | -6.7M +155.14% | -2.6M N/A | 0 +100.00% | |
Interest Income and Expense and Net | 388,000 +106.46% | -6.0M +145.32% | -2.4M -8,537.93% | 29,000 +149.15% | |
Total Nonoperating Income and Expense | -137.2M -683.18% | 23.5M +183.54% | -28.2M -97,186.21% | 29,000 -95.65% | |
Income before Taxes | -36.6M -13.67% | -42.4M +3.78% | -40.9M +10.68% | -36.9M +55.09% | |
Income Taxes | N/A N/A | N/A N/A | N/A N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -173.8M +818.79% | -18.9M -72.60% | -69.0M +87.03% | -36.9M +59.43% | |
Net Income from Continuing Operations Applicable to Common | -173.8M +818.79% | -18.9M -72.60% | -69.0M +87.03% | -36.9M +59.43% | |
Basic EPS and Net Income | -4.80 +823.08% | -0.52 -72.77% | -1.91 +76.85% | -1.08 +12.50% | |
Diluted EPS and Net Income | -4.80 +439.33% | -0.89 -53.40% | -1.91 +76.85% | -1.08 +12.50% | |
Basic Weighted Average Shares | 36.2M +0.22% | 36.2M +0.24% | 36.1M +5.19% | 34.3M +42.27% | |
Diluted Weighted Average Shares | 36.2M -38.64% | 59.1M +63.71% | 36.1M +5.19% | 34.3M +42.27% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 8.7M -6.49% | 9.3M -31.29% | 13.5M -8.95% | 14.9M +44.36% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 8.7M -6.49% | 9.3M -31.29% | 13.5M -8.95% | 14.9M +44.36% | |
Total Current Assets | 10.7M -5.66% | 11.3M -40.95% | 19.2M -29.19% | 27.0M +80.37% | |
Accumulated Depreciation | 14.0M +6.80% | 13.1M +11.21% | 11.8M +6.47% | 11.1M +8.59% | |
Property and Plant and Equipment and Net | 12.2M -7.91% | 13.2M +5.43% | 12.6M +247.22% | 3.6M +62.93% | |
Total Long-Term Assets | 973,000 -0.21% | 975,000 -60.53% | 2.5M +1.69% | 2.4M +38.40% | |
Total Assets | 76.9M -11.05% | 86.4M -12.12% | 98.4M +2.64% | 95.8M +37.36% | |
Income Taxes Payable | 3.1M 0.00% | 3.1M 0.00% | 3.1M 0.00% | 3.1M 0.00% | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | 1.2M 0.00% | |
Total Current Liabilities | 8.9M -81.46% | 48.2M +193.11% | 16.5M -33.82% | 24.9M +416.68% | |
Total Long-Term Debt | 256.9M +363.46% | 55.4M -32.65% | 82.3M N/A | N/A N/A | |
Total Long-Term Liabilities | 32.7M -3.43% | 33.8M -2.56% | 34.7M -8.49% | 38.0M -10.97% | |
Total Liabilities | 295.5M +119.76% | 134.5M +3.09% | 130.4M +118.27% | 59.8M +34.67% | |
Retained Earnings | -501.5M +53.03% | -327.7M +6.13% | -308.8M +28.80% | -239.8M +18.20% | |
Total Stockholders Equity | -218.6M +355.23% | -48.0M +49.76% | -32.1M -188.87% | 36.1M +42.06% | |
Total Shares Outstanding | 36.4M +0.69% | 36.2M +0.17% | 36.1M -0.06% | 36.1M +33.31% | |
Cash Flow | |||||
Cash from Operating Activities | -25.8M -31.39% | -37.6M -20.82% | -47.4M +46.00% | -32.5M +37.78% | |
Capital Expenditures | 542,000 -71.15% | 1.9M -76.93% | 8.1M +268.34% | 2.2M +69.56% | |
Cash from Investing Activities | -542,000 -71.15% | -1.9M -76.90% | -8.1M +267.89% | -2.2M +69.56% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 25.6M -26.73% | 35.0M -35.25% | 54.0M +22.66% | 44.0M +72.49% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | -212.83% +939.64% | -20.47% -71.21% | -71.11% +59.49% | -44.59% +5.21% | |
Return on Equity | 130.37% +175.98% | 47.24% +101.37% | -3,439.35% +2,763.74% | -120.10% +14.77% | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 1.19 +408.70% | 0.23 -79.85% | 1.16 +6.99% | 1.09 -65.09% | |
Cash Ratio | 0.97 +404.21% | 0.19 -76.56% | 0.82 +37.58% | 0.60 -72.06% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow